For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Learn More » For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45 ...

Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...